Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
Jamie N. Anastas, Barry M. Zee, Jay H. Kalin, et al.
Cancer Cell (2019) Vol. 36, Iss. 5, pp. 528-544.e10
Open Access | Times Cited: 160

Showing 1-25 of 160 citing articles:

Epigenetic mechanisms in breast cancer therapy and resistance
Liliana Garcia-Martinez, Yusheng Zhang, Yuichiro Nakata, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 331
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li Guo, Yuan Tian, Wei‐Guo Zhu
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 267
The Glioma Stem Cell Model in the Era of Single-Cell Genomics
Mario L. Suvà, Itay Tirosh
Cancer Cell (2020) Vol. 37, Iss. 5, pp. 630-636
Open Access | Times Cited: 234
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Sriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2370-2393
Open Access | Times Cited: 79
LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials
Beatrice Noce, Elisabetta Di Bello, Rossella Fioravanti, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 73
Signaling pathways in brain tumors and therapeutic interventions
Shenglan Li, Can Wang, Jinyi Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 52
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy
Liang Shen, Bo Wang, ShaoPeng Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 922-951
Closed Access | Times Cited: 16
Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas
Chan Chung, Stefan R. Sweha, Drew Pratt, et al.
Cancer Cell (2020) Vol. 38, Iss. 3, pp. 334-349.e9
Open Access | Times Cited: 136
The Chemical Biology of Reversible Lysine Post-translational Modifications
Zhipeng A. Wang, Philip A. Cole
Cell chemical biology (2020) Vol. 27, Iss. 8, pp. 953-969
Open Access | Times Cited: 130
H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2
Siddhant U. Jain, Andrew Q. Rashoff, Samuel D. Krabbenhoft, et al.
Molecular Cell (2020) Vol. 80, Iss. 4, pp. 726-735.e7
Open Access | Times Cited: 109
LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target
Panagiotis Karakaidos, John Verigos, Angeliki Magklara
Cancers (2019) Vol. 11, Iss. 12, pp. 1821-1821
Open Access | Times Cited: 94
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective
Xing‐Jie Dai, Ying Liu, Xiao-Peng Xiong, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 23, pp. 14197-14215
Closed Access | Times Cited: 77
Glioblastoma: Current Status, Emerging Targets, and Recent Advances
Amandeep Thakur, Chetna Faujdar, Ram Sharma, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8596-8685
Open Access | Times Cited: 68
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5
Ye Sun, Kun Yan, Yi Wang, et al.
Nature Cancer (2022) Vol. 3, Iss. 9, pp. 1105-1122
Open Access | Times Cited: 39
BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Eshini Panditharatna, Joana G. Marques, Tingjian Wang, et al.
Cancer Discovery (2022), pp. OF1-OF26
Open Access | Times Cited: 39
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Jing Ye, Junhao Wu, Bo Liu
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 3, pp. 188866-188866
Closed Access | Times Cited: 27
The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma
Muzhou Wu, Ailish Hanly, Frederick Gibson, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 6
Open Access | Times Cited: 9
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models
Nicholas A. Vitanza, Matthew C. Biery, Carrie Myers, et al.
Neuro-Oncology (2020) Vol. 23, Iss. 3, pp. 376-386
Open Access | Times Cited: 57
Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy
Keng Po Lai, Jian Chen, William Ka Fai Tse
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2548-2548
Open Access | Times Cited: 51
LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma
Lukas Leiendecker, Pauline S. Jung, Izabela Kręcioch, et al.
EMBO Molecular Medicine (2020) Vol. 12, Iss. 11
Open Access | Times Cited: 50
OTUD7B Deubiquitinates LSD1 to Govern Its Binding Partner Specificity, Homeostasis, and Breast Cancer Metastasis
Zhicheng Gong, Aicun Li, Jian‐cheng Ding, et al.
Advanced Science (2021) Vol. 8, Iss. 15
Open Access | Times Cited: 46
New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
Davis P. Argersinger, Sarah Rivas, Ashish H. Shah, et al.
Cancers (2021) Vol. 13, Iss. 21, pp. 5280-5280
Open Access | Times Cited: 46
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma
Chen He, Ke Xu, Xiaoyan Zhu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 44
Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle
Valentina Di Ruscio, Giada Del Baldo, Francesco Fabozzi, et al.
Diagnostics (2022) Vol. 12, Iss. 9, pp. 2064-2064
Open Access | Times Cited: 36
A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities
Michael McNicholas, Antonella De Cola, Zahedeh Bashardanesh, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1592-1615
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top